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Abstract 
  Oral mucositis (OM) is a frequent adverse effect of allogenic or autologous 
hematopoietic stem cell transplantation (HSCT). It results from direct toxic injury to the 
mucosal epithelial cells by the immunosuppressive regimen. Here we compared the 
incidence and severity of OM between a group of 24 patients who received proper oral 
management during HSCT and a group of 24 who did not. The oral management group 
received pre-HSCT instruction on oral care and an oral examination in the clean room. 
Differences in the incidence and severity of OM between the two groups were examined 
statistically. OM was observed in 14 (58.3%) patients in the oral management group and 22 
(91.6%) in the control group. The median of the OM score was 1 for the oral management 
group (range 0 to 3) and 2 for the control group (range 0 to 3). There was a significant 
difference in the OM score (P<0.05) and in the incidence of OM between the two groups 
(P<0.01). This study shows that oral management may decrease the occurrence of OM. Our 
results also suggest that it is important to include an oral management provider on the 
HSCT team. 
 
Key Words: oral mucositis (OM); oral management; hematopoietic stem cell 
transplantation (HSCT); oral management provider 
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Introduction 
    Hematopoietic stem cell transplantation (HSCT) has become an important treatment 
for myelosuppressed patients with hematological diseases, including acute and chronic 
leukemias, aplastic anemia, myelodysplastic syndromes, and lymphomas1,2. Oral mucositis 
(OM) is one of the most frequent adverse effects of allogenic or autologous HSCT. It is 
caused by direct toxic injury to the mucosal epithelial cells. Successful engraftment after 
HSCT often requires severe myelosuppression, which is accomplished by total body 
irradiation (TBI), chemotherapy, or a combination of these therapies. These 
immunosuppressive regimens are toxic to cells and increase the chance of OM.  
In one study of HSCT patients, 99% experienced OM, and 67.4% of them had a 
WHO OM grade of 3 or 4. The OM was treated with strong opiate analgesia for a median of 
6 days in 47% of these patients3. Mucositis places immunocompromised patients at risk for 
bacteremia and sepsis. OM also appears to be a significant cost driver in HSCT, as it is 
associated with an increase in the length of hospital stay and higher inpatient charges4. 
 OM results in significant morbidity and impairment of the patients’ quality of life. 
The most common signs and symptoms of OM are erythema, edema, burning sensation, 
increased sensitivity to hot and spicy foods, white patches on mucous membranes of the 
cheeks, lips, tongue and palate, and subsequent painful ulcers. The latter make it hard to 
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swallow, which leads to malnutrition and dehydration, and consequently affect mucosal 
regeneration5. 
    OM lesions usually disappear after recovery without scar formation, unless the OM is 
worsened by severe infection6. Sonis et al. found a relationship between OM and 
bacteremia, and concluded that poor oral care management could lead to infected oral 
ulcers and the dissemination of infection7. Evidence-based clinical practice guidelines for 
the care of patients with oral and gastrointestinal mucositis in 2005 newly recommended 
the use of palifermin for OM associated with HSCT, and cryotherapy for OM associated 
with high doses of melphalan. To reduce the severity of OM from chemotherapy and/or 
radiotherapy, oral care includes multidisciplinarily developed and evaluated oral care 
protocols, and patient and staff education on the use of such protocols8. It is also suggested 
that an experienced oral care provider, that is, a dentist, dental hygienist, or nurse, should 
be included on the HSCT team. However, although an oral management protocol during 
HSCT has been recommended, few prospective studies have examined its effectiveness9,10.  
    The purpose of this study was to compare the incidence and severity of OM between a 
group of patients who received proper oral management during HSCT and a group of 
patients who did not. 
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Patients and methods 
     Forty-eight patients suffering from hematologic malignancies who underwent 
allogeneic or autologous HSCT were enrolled in this study retrospectively (Table 1). The 
patients were divided into two groups: the oral management group, which consisted of 24 
patients who received oral management during HSCT beginning in 2009, and the control 
group, which consisted of 24 HSCT patients treated in 2007 to 2008, who did not receive 
oral management. The ethical committee of Tsukuba University Hospital approved this 
study. 
       All 48 patients received an oral examination prior to transplantation by the same 
two trained oral health-care professionals. Panoramic radiographs of all the patients were 
taken. The caries, apical and marginal periodontitis, and impacted third molar were 
managed according to our previous reports,11-13 and all the dental management was 
completed before HSCT. The details of the treatment were as follows. Teeth with dental 
caries were restored in patients with sufficient time for dental treatment, but observed in 
those without enough time. Teeth with recently symptomatic apical periodontitis or 
asymptomatic apical periodontitis and periapical radiolucency of the maximal diameter, 
i.e., greater than 5 mm, were treated with root canal or dental extraction. In cases of 
marginal periodontitis, teeth with gingival swelling, pain, and purulent discharge, a 
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probing depth greater than 8 mm, or severe mobility were removed, while teeth without 
these signs and symptoms were observed. Tooth brushing instruction and/or scaling was 
provided. Partially erupted third molars affected by pericoronitis or purulent drainage 
were extracted, and asymptomatic third molars were not treated.  
   For the oral management group, oral care instruction for the patients was included in 
the transplantation conference with the HSCT team before HSCT. These patients received 
an additional oral examination in the clean room and instructions for tooth brushing and 
swab use, according to the condition of OM by the dentist and dental hygienist. In both 
groups, OM was treated with azulene sodium sulfate and a 4% lidocaine mouth rinse. To 
treat the oral pain, indomethacin intra-oral spray and/or intravenous fentanil were 
administered during HSCT (Fig 1).  
     The OM was graded by the nurses of HSCT units using the National Cancer Institute 
common toxicity criteria (NCI, CTC) Common Terminology Criteria for Adverse Events 
(CTCAE, ver. 3.0), as follows: Grade 0, none; Grade 1, painless ulcers, erythema, and/or 
mild soreness without lesion; Grade 2, painful erythema, edema or ulcers, but able to 
swallow; Grade 3, painful erythema, edema, or ulcers preventing swallowing or requiring 
hydration or parenteral nutrition support; Grade 4, severe ulceration requiring 
prophylactic intubation or resulting in documented aspiration pneumonia (Fig. 2). 
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    Differences in the patient characteristics and the incidence and severity of OM between 
the two groups were determined using the Mann-Whitney U test or Fisher’s exact probably 
test and the chi-square for independence test. A level of P<0.05 was considered statistically 
significant. 
 
Results  
    The hematologic diagnoses were as follows: 14 patients had malignant lymphoma 
(ML), 13 had acute myeloid leukemia (AML), 7 had acute lymphoid leukemia (ALL), 4 had 
myelodysplastic syndrome (MDS), 4 had multiple myeloma (MM), and 6 had others (Table 
1). The hematopoietic stem cells were collected from the bone marrow of 20 patients, the 
peripheral blood of 18, and from umbilical cord blood for 10. The pre-transplant 
conditioning agents included cyclophosphamide (Cy) and total body irradiation (TBI) for 
21 patients, ifosphamide , carboplatin, and etoposide (ICE) for 7, fludarabine (Flu) and 
others for 6, and others for 14. The dose and schedule of Cy was 60mg/kg (day -3, -2), ICE 
was consisting from ifosphamide 3,000mg/m2, carboplatin 400mg/m2 and etoposide 
400mg/m2 (day-5~-2) and Flu was 25~30mg/m2 (day -6~-2). TBI was performed for 27 
(56.3%) patients, including 16 (66.7%) in the oral management group and 11 (45.8%) in the 
control group (Table 1).  
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    The 48 patients included 23 males and 25 females, ranging in age from 16 to 66 years 
with a median of 45 years (Table 2). There were no significant differences in age or gender 
between the patients in the oral management and control groups. Allogeneic 
transplantation was performed for 21 patients in the oral management group and 14 in the 
control group, which represented a significant difference (P<0.05). Of the conditioning 
agents, the ICE and Flu +Mel/TBI regimens were significantly different between the two 
groups (P<0.05). The median number of days with WBC less than 1,000/µl was 19.5 for the 
oral management group and 11.5 for the control group, which was a significant difference 
(P<0.01). 
  The median of the minimum WBC was 0 (range 0-700/µl) for patients in the oral 
management group, and 0 (range 0-200/µl) for those in the control group. The median 
number of days in which the patients’ temperature was higher than 38 degrees centigrade 
was 6 (range 0-18) for the oral management group, and 4.5 (range 0-31) for the control 
group. These differences in fever duration and minimum WBC were not significantly 
different between the patients in the two groups (Table 2).  
       OM was observed 14 (58.3%) patients in the oral management group and 22 (91.6%) 
in the control group (Table 3). The incidence of OM according to CTCAE ver.3.0 is shown 
in Fig. 3. Grade 0 was observed in 10 patients in the oral management group and 2 in the 
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control group, which was a significant difference (P<0.01). No patient was observed with 
grade 4 in either group. The median of the worst OM score was 1 for the oral management 
group (range 0-3), and 2 for the control group (range 0-3), and the difference was 
significant (P<0.05).  
    The duration of oral pain from OM in the two groups is shown in Table 3. The median 
number of days of oral pain was 0.5 (range 0 to 21) in the oral management group and 8 
(range 0 to 22) in the control group. Although there was no significant difference between 
the two groups, there was a tendency towards a reduced duration of oral pain in the oral 
management group (P<0.1). 
    Fentanil administered to patients with oral pain, a sore throat, or other systemic pain. 
The median total dose of fentanil during HSCT was 1.35 mg (range 0 to 7.7 mg) for the oral 
management group and 3.95 mg (range 0 to 25 mg) for the control group, which was not 
significantly different. 
  The symptom suspecting intestinal mucositis as vomiting, diarrhea and full total 
parenteral nutrition use was observed in 4 patients in the oral management group and 3 in 
the control group. Sepsis occurring from OM was observed in 2 patients in the oral 
management group and 3 in the control group, which was not significantly different (Table 
3). All the patients recovered after receiving antibiotics. 
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Discussion 
   OM is a prominent adverse effect of the toxicity of the conditioning regimen used for 
HSCT, and is typically seen within 2 weeks14. Moderate to severe mucositis interferes with 
oral nutrition and quality of life, and frequently leads to secondary infection in HSCT 
recipients. Therefore, an effective prophylaxis for OM is crucial for improving the 
treatment outcome of HSCT. Mouth rinsing with water or mouthwash is generally 
recommended as routine care in patients with OM to reduce the risk of 
mucositis-associated infection 10. Although there was no significant difference in the 
occurrence of sepsis between our two groups of patients, more than 90% of the patients in 
the control group developed OM. OM of Grade 2 and 3 was observed in about 70% of this 
group. 
    Filicko et al. reviewed the special recommendations for patients undergoing HSCT14. 
These include a pre-transplant oral evaluation by a qualified dentist, good routine oral 
health maintenance during the peri-transplant period, and the maintenance of adequate 
platelet and neutrophil counts to improve healing. In a recent report, we also suggested the 
importance of including an experienced oral management provider on the HSCT team15. 
Oral management providers at our hospital include dentists, dental hygienists, and HSCT 
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unit nurses. In the present study, the oral management group received pre-HSCT oral care 
instruction, and the control group did not. The instruction on self oral management was 
provided by a dental hygienist pre-HSCT, and an oral care provider participated in the 
pre-HSCT conference. During HSCT, the oral examination was performed in the clean 
room by a dentist and dental hygienist, and additional instruction on oral care was 
provided at this time. Since an oral care provider began participating in patient care 
throughout the HSCT, the occurrence rate of OM has decreased from about 90%, to about 
60%. The symptoms of intestinal mucositis were in the same incidence of both groups in 
our study. The oral mucositis decreased clearly in the oral management group. Therefore 
this improvement was clearly owing to the participation of the oral care provider during 
HSCT. These findings indicate that an experienced dental provider is a necessary and 
valuable member of the HSCT team, and that instruction on self care before HSCT, and an 
oral examination and advice on oral care given to patients in the clean room by the oral 
care provider are very effective for preventing OM. 
   The incidence of OM is reported to be 80-99% in patients receiving a myeloablative 
conditioning regimen3,16 and the incidence of a toxicity grade of 3 or 4 is reported to be 
67.4-98%3,17. In the present study, the incidence of OM for the control group agreed with 
previous reports; however, it was decreased to < 60% in the oral management group. The 
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incidence of OM of CTCAE grade 3 decreased from 29% to 20.8% after the oral 
management intervention. The toxicity grades for OM according to the WHO and 
NCI-CTC criteria are similar; the WHO criteria focus on oral intake and CTCAE focus on 
the ability to swallow 14. In our study, the CTCAE were used as follows: Grade 1 was mild, 
Grade 2 was moderate, Grade 3 was severe, and Grade 4 was life threatening6. It is 
noteworthy that grade 0 OM was observed 41.7% of the patients in the oral management 
group, but only 8.3% of those in the control group in the present study. However, the 
number of patients with grade 3 OM did not decrease significantly in the oral management 
group compared with the control group, suggesting that oral management intervention 
may decrease not the grade, but the occurrence of OM. 
    The regimens incurring the most severe OM are reported to be high-dose melphalan, 
followed by busulphan, cyclophosphamide/TBI, cyclophosphamide/carmustine, and 
cyclophosphamide/etoposide/carmustine 3. In the present study, more patients in the oral 
management group had the fludarabine/melphalan/TBI regimen than in the control group, 
which could have caused a bias toward a greater occurrence of OM in the oral management 
group. Moreover patients of the oral management group had more allogeneic 
transplantations and median number of days of WBC<1,000/ υl significantly. These factors 
effect to make a severe OM. However, despite these severe conditions, the incidence of OM 
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clearly decreased in the oral management group. A future trial will be required to confirm 
the efficacy of oral management in the same regimens to exclude a bias. Concomitant TBI 
during the conditioning therapy for stem-cell transplantation is also reported to increase 
the risk of developing OM18-20. In our patients, 27 patients (56.3%) received TBI. We did not 
find any relationship between TBI and the occurrence of OM by univariate analysis. 
     The panel in 2005 suggested that interdisciplinary systematic oral care protocols 
geared toward the individual needs of each patient be developed. These protocols include 
educational approaches involving the patient, the patient’s family, and the hospital staff, 
and quality-improvement processes for evaluating them. A preventive oral care regimen 
should be part of the routine supportive care in HSCT, along with therapeutic oral care if 
OM develops. A standardized oral care protocol involving regular, systematic, oral care 
hygiene with brushing, flossing, bland rinses, and oral moisturizers should be 
implemented for all patients. An interdisciplinary approach to oral care (for example, by a 
nurse, physician, dentist, dental hygienist, and others as relevant) will provide the most 
comprehensive supportive care8. Our results support the inclusion of an oral management 
provider on the HSCT team. In this study, the mechanism by which oral management 
reduced the OM incidence was not clear. A future trial will be required to confirm the 
efficacy of this practice and to elucidate the preventive mechanism. 
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Conclusion 
   This study shows that oral management may decrease, not the grade, but the 
occurrence of OM. Our results support the inclusion of an oral management provider on 
the HSCT team. 
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Fig 2. OM according to NCI, CTCAE ver.3.0  
  Grade 0, none; Grade 1, painless ulcers, erythema, and/or mild soreness without lesion; Grade 2, painful erythema, edema or ulcers, but 
able to swallow; Grade 3, painful erythema, edema, or ulcers preventing swallowing or requiring hydration or parenteral nutrition support; 
Grade 4, severe ulceration requiring prophylactic intubation or resulting in documented aspiration pneumonia.   
 
  
Fig 3. Worst oral mucositis grade according to CTCAE ver. 3.0  
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Table 1. Oncologic diagnoses and treatment 
 
Disease                                No. of patients                   
               Oral management group (n=24)    Control group (n=24)         Total 
ML                         4                   10                        14 
AML       9                    4                        13 
ALL                        2                    5                         7 
MDS       4    0                         4 
MM       2    2             4 
AA       2    1             3 
Others        1    2             3 
 
Type of transplantation                 No. of patients  
              Oral management group (n=24)    Control group (n=24)          Total 
BMT        9     11            20 
PBSCT        7    11            18 
UCBT        8    2            10 
 
Pre-transplant conditioning agents          No. of patients  
           Oral management group (n=24)    Control group (n=24)      Total 
Cy/TBI                      10                      11                   21 
ICE                          1                       6                    7 
Flu+others                     4                       2                    6 
Flu+Mel/TBI                   5                       0                    5 
Cy+others                     2                       2                    4 
Mel                          2                       2                    4 
Others                        0                       1                    1 
  
Total body irradiation           16                       11                27 (56.3%) 
 
ML, malignant lymphoma; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; MDS, 
myelodysplastic syndrome; MM, multiple myeloma; AA, aplastic anemia; BMT, bone marrow 
transplantation; PBSCT, peripheral blood stem cell transplantation; UCBT, umbilical cord blood 
transplantation 
Cy, cyclophosphamide; TBI, total body irradiation; ICE, ifosphamide, carboplatin, etoposide; 
Flu, fludarabine; Mel, melphalan 
Table 2. Patient characteristics 
 
Characteristic              Oral management (n=24)             Control (n=24)       P  
Median age, years (range)              48 (20-63)    41.5 (16-66)         n.s. 
 
Gender (male/female)                 10/14         13/11           n.s. 
 
Type of transplant                    21/3                    14/10       <0.05 
 (allogeneic/autologous)               
Median number of days        19.5 (1-61)            11.5 (4-79)         <0.01 
  of WBC<1,000/μl (range)                                 
Median of minimum WBC,          0 (0-700)     0 (0-200)          n.s.     
  /μl (range) 
Median number of febrile days         6 (0-18)    4.5 (0-31)      n.s. 
  (>38ºC) (range) 
n.s., not significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Characteristics of oral mucositis in the oral management and control groups 
 
Characteristics                  Oral management (n=24)   Control (n=24)       P 
Median of worst oral                    1 (0-3)              2 (0-3)           <0.05 
mucositis score (CTCAE ver 3.0)        
Oral mucositis (OM)                   14 (58.3%)          22 (91.6%)         <0.01 
 
Median number of days with oral pain     0.5 (0-21)           8 (0-22)            n.s. 
 
Median total dose of fentanyl (mg)       1.35 (0-7.7)         3.95 (0-25)           n.s. 
 
Sepsis from oral mucositis               2                   3                n.s. 
n.s., not significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
